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Abstract
Background: Previous studies have shown that testosterone enhances baroreflex bradycardia.
Therefore, conscious unrestrained rats were used to investigate the role of the androgen receptor
in the testosterone-mediated modulation of baroreflex bradycardia. Androgen depletion (3 weeks),
and androgen receptor blockade (20–24 h), were implemented to test the hypothesis that
testosterone influences baroreflex bradycardia via its activity at the androgen receptor in male rats.
Phenylephrine (1–16 ?g kg-1) was used to assess baroreflex bradycardia.
Results: Androgen depletion attenuated baroreflex bradycardia (P < 0.01). The antiandrogen
flutamide (5, 15, or 30 mg kg-1, s.c.) caused dose-related attenuation of baroreflex bradycardia in
spite of a significant (P < 0.05) increase in serum testosterone. The latter did not lead to increased
serum 17?-estradiol level.
Conclusion: The data suggest: 1) Androgen depletion or adequate androgen receptor blockade
attenuates baroreflex bradycardia. 2) The reflex increase in serum testosterone may
counterbalance the action of the lower doses (5 or 15 mg kg-1) of flutamide. 3) The absence of a
change in serum 17?-estradiol rules out its contribution to flutamide action on baroreflex
bradycardia.
Background
Most of the research concerning the effects of gonadal
hormones on the baroreflex bradycardia has focused on
17?-estradiol. However, our preliminary findings [1],
confirmed later by El-Mas et al. [2], have provided evi-
dence that androgens (including testosterone) play an
important role in the mediation of baroreflex bradycardia.
Reported findings including ours [2-4] have shown that
testosterone depletion attenuates baroreflex-mediated
bradycardia and that a restoration of baroreflex-mediated
bradycardia occurs subsequent to testosterone replace-
ment.
Although the effect of androgens on baroreflex bradycar-
dia has been previously reported, no studies have investi-
gated the possible involvement of the androgen receptor
in mediating the effect of testosterone on baroreflex
bradycardia. Therefore, flutamide, a relatively lipophilic
nonsteroidal competitive central and peripheral androgen
receptor blocker devoid of mixed agonist/antagonist
effects [5-8] was used in the present study. Notably, there
are two actions that must be considered when flutamide is
administered. First, it leads to significant elevation in
serum testosterone due to its ability to increase plasma
levels of lutenizing hormone (LH) via preventing the acti-
vation of the testosterone-mediated negative feedback
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influence on the hypothalamic-pituitary axis [6,9]. Sec-
ond, it is possible that the increase in serum testosterone
will result in an increase in 17?-estradiol, due to aromati-
zation of testosterone to 17?-estradiol via the enzyme aro-
matase [10]. Like testosterone, 17?-estradiol enhances
baroreflex bradycardia in male rats [11]. Flutamide causes
an increase in plasma dihydrotestosterone (DHT) in male
Sprague-Dawley (SD) rats [12]. The increase in serum tes-
tosterone compromises flutamide clinical efficacy [6,9].
Nonetheless, the ability of flutamide to penetrate the
blood brain barrier [8], its relatively pure antiandrogenic
activity [5], and its similar affinities for the androgen
receptor in various androgen-sensitive tissues [14], make
this drug a useful agent in investigating the role of the cen-
tral and peripheral androgen receptor in androgen-medi-
ated responses. In addition, previous research has shown
that a gender difference exists in the baroreflex-mediated
bradycardia in young rats [15]. Male rats exhibited a
greater vagal outflow to the heart in response to barore-
ceptor activation versus age-matched female rats [15]. Tes-
tosterone's contribution to the vagal outflow and not to
the sympathetic outflow to the heart of male rats was con-
firmed by El-Mas et al. [2].
Hence, the main objective of this study was to test the
hypothesis that androgens act via the androgen receptor
to enhance the baroreflex sensitivity (baroreflex bradycar-
dia) in male rats. The hypothesis was tested by determin-
ing whether a) androgen depletion causes an attenuation
of baroreflex bradycardia, b) androgen receptor blockade
by the competitive antiandrogen, flutamide (5, 15, or 30
mg kg-1, s.c.), produces a dose-dependent inhibition of
baroreflex bradycardia, and c) the reflex increase in testo-
sterone, which follows androgen receptor blockade [6,9]
leads to an increase in serum 17?-estradiol. The studies
were undertaken in conscious instrumented rats to avoid
the confounding effects of anesthesia [16].
Results
Effect of androgen depletion on baroreceptor reflex 
control of heart rate
Baseline mean arterial pressure and heart rate values were
similar between the sham-operated and orchiectomized
rats (mean arterial pressure – sham: 113 ± 1.6 vs. orchiec-
tomized: 109 ± 2.1 mmHg; heart rate – sham: 420 ± 10 vs.
orchiectomized: 434 ± 7 beats min-1; P > 0.05). All base-
line values were obtained on the day of the experiment.
Phenylephrine elicited similar rises in mean arterial pres-
sure in all groups (Figure 1A). However, at any given rise
in blood pressure, the reflex bradycardic response was sig-
nificantly attenuated in castrated rats (P < 0.01, Figures 1B
and 2). Therefore, the baroreflex bradycardia was signifi-
cantly reduced compared with the sham-operated rats (-
1.23 ± 0.11 vs. -1.84 ± 0.24 beats min-1 mmHg-1; Figure
2). This represented an approximately 30% reduction in
Dose-Response curves subsequent to androgen depletionFigure 1
Dose-Response curves subsequent to androgen 
depletion. Dose-Response curves relating increments in 
mean arterial pressure (MAP) evoked by phenylephrine (L-
PE) (A) to decreases in heart rate (HR) (B) in conscious 
unrestrained orchiectomized and sham-operated (Sham) 
rats. Data are means ± SEM. Numbers in parentheses are 
number of observations. Student's t-test, ** P < 0.01 vs. 
sham-operated.
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baroreflex bradycardia. Serum testosterone levels declined
subsequent to orchiectomy (9.0 ± 0.4 vs. 487 ± 94.1 ng/
dl, P < 0.0001).
Effect of androgen receptor blockade on baroreceptor 
reflex control of heart rate
Baseline values of mean arterial pressure and heart rate
obtained on the day of the experiment were similar for the
treatment and control groups (Table 1). The effect of fluta-
mide (5, 15, or 30 mg kg-1, s.c.) on baroreflex bradycardia
was assessed 20–24 h after drug administration. Phenyle-
phrine elicited similar rises in mean arterial pressure in all
groups (Figure 3A). However, only the highest dose of
flutamide produced a significant (P < 0.01, Figures 3B and
4) attenuation of the baroreflex-mediated bradycardia (-
1.07 ± 0.14 vs. -1.97 ± 0.27 beats min-1 mmHg-1, P < 0.01,
Figure 4); a reduction of approximately 45%. Although
the reduction elicited by the 2 lower doses of flutamide
did not reach statistical significance, (5 mg kg-1: -1.57 ±
0.23, and 15 mg kg-1: -1.48 ± 0.21 vs. vehicle: -1.97 ± 0.27
beats min-1 mmHg-1, P > 0.05; Figure 4), a significant
inverse correlation (r = -0.4, P < 0.05, Figure 5) was
observed between baroreflex bradycardia and all doses of
flutamide. In all treatment groups, flutamide elicited sig-
nificant (P < 0.05) rises in serum testosterone, which were
not dose-related (Figure 6A). Treatment with flutamide
did not change serum 17?-estradiol (P > 0.05; Figure 6B).
Discussion
The current study presents three new findings. First,
androgen receptor blockade by the competitive antian-
drogen flutamide attenuates baroreflex sensitivity
(baroreflex bradycardia), which suggests the involvement
of the androgen receptor in the androgen-mediated
enhancement of baroreflex bradycardia in sexually mature
male rats. Second, the associated reflex increase in serum
testosterone caused by flutamide, which competitively
inhibits flutamide activity at the androgen receptor [6,9],
may have counteracted the effect of the lower doses of
flutamide on baroreflex bradycardia. Third, serum 17?-
estradiol level did not change in spite of the significant
elevation in serum testosterone in flutamide-treated rats,
which rules out the involvement of 17?-estradiol in coun-
teracting flutamide's influence on baroreflex bradycardic
responses.
We report here, for the first time, that flutamide attenuates
baroreflex bradycardia, which suggests the involvement of
the androgen receptor in the androgen-mediated facilita-
tion of baroreflex bradycardia. In a preliminary study [1]
later confirmed by El-Mas et al. [2], we determined that
androgen depletion produced a 30% reduction in barore-
flex bradycardia, which suggests that androgens are neces-
sary for the maintenance of baroreflex bradycardia in
sexually mature young male rats. The consequence of
androgen receptor blockade on baroreflex bradycardia
was investigated to elucidate a mechanism for the previ-
ously determined androgen-mediated facilitation of
Table 1: Mean arterial pressure (MAP) and heart rate (HR) values obtained in conscious rats 20–24 h following flutamide (5, 15 or 30 
mg/kg) or equal volume of vehicle. Data presented as means ± SEM.
Group n MAP (mmHg) HR (beats min-1)
Vehicle 9 105 ± 4 459 ± 19
Flutamide (5 mg/kg) 9 111 ± 4 456 ± 14
Flutamide (15 mg/kg) 12 105 ± 2.6 465 ± 12
Flutamide (30 mg/kg) 18 104 ± 2.7 460 ± 8
Effect of androgen depletion on baroreflex sensitivityFigure 2
Effect of androgen depletion on baroreflex sensitiv-
ity. Baroreflex curves relating decreases in heart rate (HR) 
to increments in mean arterial pressure (MAP) evoked by 
phenylephrine and baroreflex sensitivity; beats min-1 mmHg-1 
in conscious unrestrained orchiectomized (O) and sham-
operated (SO) rats. Data are means ± SEM. Numbers in 
parentheses are number of observations. Student's t-test, ** 
P < 0.01 vs. sham-operated.
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baroreflex bradycardia in male rats [2]. Remmers et al.
[21] showed that androgen receptor blockade can be
achieved in rats 20–24 h after flutamide administration.
Therefore, a similar treatment regimen was adopted in
addition to using 3 doses of flutamide (5, 15, or 30 mg kg-
1, s.c.) to determine a possible dose-dependent effect via
the androgen receptor on baroreflex bradycardia. A signif-
icant inverse correlation was observed between baroreflex
bradycardia and the doses of flutamide, suggesting that
the higher the dose of flutamide, the greater the reduction
in baroreflex-mediated bradycardia. The substantial
reductions in baroreflex bradycardia observed following
androgen receptor blockade and androgen depletion were
not significantly different. It is notable, however, that the
findings of the present study pertain to androgen modula-
tion of the bradycardic component of the cardiac barore-
flex response. Whether androgen receptor blockade affects
similarly or differently the tachycardic response (tested by
nitroprusside) remains to be investigated.
Some evidence, although controversial, suggest that
androgens may confer some cardiovascular protection
[22-26]. Consistent with this view are the present findings
that androgens enhance baroreflex bradycardia via the
androgen receptor. The flutamide-induced attenuation of
baroreflex bradycardia, if continued on a chronic basis,
may lead to hypertension, because in some models of
hypertension, an attenuated baroreflex sensitivity plays a
contributory role [27]. In effect, some reports indicate that
chronic flutamide treatment can produce cardiovascular
problems [22], including hypertension [24] in some pros-
tate cancer patients. By contrast, Ganten et al. [28] and
Reckelhoff et al. [29] demonstrated an antihypertensive
effect for flutamide in young male spontaneously hyper-
tensive rats. In these reported studies, the changes in
blood pressure resulted from chronic flutamide treat-
ment, while in the present study a single dose of flutamide
was administered to normotensive rats.
The lower doses of flutamide failed to inhibit baroreflex
bradycardia, which may be attributed to an associated
reflex increase in serum testosterone and 17?-estradiol.
The flutamide-induced increase in serum testosterone
[6,9], as well as the higher affinity of testosterone for the
androgen receptor [14], enable testosterone to compete
with flutamide at the androgen receptor. Therefore, the
reflex increase and the higher affinity of serum testoster-
Effect of androgen receptor blockade on baroreflex sensitiv-ityFigure 4
Effect of androgen receptor blockade on baroreflex 
sensitivity. Baroreflex curves relating decreases in heart 
rate (HR) to increments in mean arterial pressure (MAP) 
evoked by phenylephrine and baroreflex sensitivity (beats 
min-1 mmHg-1) in conscious unrestrained male rats treated 
with flutamide (Flu.: 5, 15, or 30 mg/kg) or vehicle (Veh.) 20–
24 h earlier. Data are means ± SEM. Numbers in parentheses 
are number of observations. One-Way Analysis of Variance 
(ANOVA) followed by Fisher's Least Significant Difference 
post hoc analysis, ** P < 0.01 vs. vehicle.
Inverse relationship between dose of flutamide and barore-flex sensitivityFigur 5
Inverse relationship between dose of flutamide and 
baroreflex sensitivity. Relationship between flutamide 
dose (5, 15, or 30 mg/kg, administered 20–24 h earlier) and 
baroreflex sensitivity (beats min-1 mmHg-1) in conscious 
unrestrained male rats.
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one may have counteracted the effect of the lower doses of
flutamide on baroreflex bradycardia. Contrary to our find-
ings, Wichmann et al. [30] reported no increase in serum
testosterone subsequent to flutamide treatment although
they used similar doses (10 or 25 mg kg-1, s.c.) and a sim-
ilar dosing regimen (every 24 h for 3 days). The discrep-
ancy between both studies may be attributed to their use
of male mice and/or their collection of blood samples
after euthanasia [30].
Serum 17?-estradiol derived from testosterone [10]
enhances baroreflex bradycardia in male rats [11], and
may have counteracted the inhibitory action of flutamide
on baroreflex bradycardia. However, the absence of an
increase in 17?-estradiol after a single dose flutamide
argues against a role for this hormone in the present find-
ings. Notably, 17?-estradiol elevation occurred following
chronic (?15 days) administration of flutamide
[12,31,32].
The effect of serum dihydrotestosterone (DHT) (derived
from the conversion of testosterone by the enzyme 5?-
reductase) on baroreflex bradycardia has not been investi-
gated in rats thus far. Serum DHT has a higher affinity for
the androgen receptor than testosterone [13]. In addition,
an increase in serum DHT has been demonstrated (like
serum testosterone) subsequent to flutamide treatment in
male rats [12], which may also explain the absence of an
effect of the lower doses of flutamide on baroreflex brady-
cardia. Previous studies [2,3] have demonstrated that the
attenuation of baroreflex bradycardia subsequent to testo-
sterone depletion is reversed by testosterone replacement.
In addition, we confirmed this finding [4]. This provides
strong evidence in favour of testosterone-mediated
enhancement of baroreflex bradycardia. Nonetheless, the
effect of serum DHT on baroreflex bradycardia needs to be
investigated in future studies.
The site of testosterone action on baroreflex bradycardia
remains unknown. However, the ability of flutamide to
penetrate the blood brain barrier [8], the presence of
androgen receptor mRNA in the brainstem regions which
control the baroreceptor reflex in male rats [33] and the
presence of androgen receptor protein in similar regions
in male rats [34], suggest that testosterone's effects may be
centrally mediated.
Conclusion
The present findings suggest that the attenuation of
baroreflex bradycardia by castration or androgen receptor
blockade involves the interaction between androgens
(including testosterone) and the androgen receptor.
Androgens may enhance baroreflex bradycardia via the
androgen receptor at the level of the baroafferents, the
central nervous system or the heart. However, this
remains to be determined. Flutamide-induced inhibition
of baroreflex bradycardia if continued on a chronic basis,
Dose-Response curves subsequent to androgen receptor bl ckadFigure 3
Dose-Response curves subsequent to androgen 
receptor blockade. Dose-Response curves relating incre-
ments in mean arterial pressure (MAP) evoked by phenyle-
phrine (L-PE) (A) to decreases in heart rate (HR) (B) in 
conscious unrestrained male rats treated with flutamide (Flu.: 
5, 15, or 30 mg/kg) or vehicle 20–24 h earlier. Data are 
means ± SEM. Numbers in parentheses are number of obser-
vations. One-Way Analysis of Variance (ANOVA) followed 
by Fisher's Least Significant Difference post hoc analysis, ** P 
< 0.01 vs. vehicle.
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may explain hypertension observed in flutamide-treated
patients [24]. A significant reflex increase in serum testo-
sterone, but not 17?-estradiol, seems to limit the ability of
the lower doses of flutamide to produce significant atten-
uation of baroreflex bradycardia. These findings highlight
a major role for the androgen receptor in the mediation of
the baroreceptor reflex heart rate response.
Methods
Preparation of the rats
Male Sprague-Dawley rats (Harlan Farms, Indianapolis,
IN) were used in this study. Arterial blood pressure was
measured according to the method used in our previous
studies [17]. Briefly, the rats were anesthetized with meth-
ohexital sodium (50 mg kg-1, i.p.). Catheters (polyethyl-
ene 10 connected to polyethylene 50), filled with
heparinized saline (100 U ml-1), were placed in the
abdominal aorta and vena cava via the femoral artery and
vein for measurement of blood pressure and i.v. adminis-
tration of drugs, respectively. The catheters were inserted
about 5 cm into the femoral vessels and secured in place
with sutures. Finally, the catheters were tunnelled s.c.,
exteriorized at the back of the neck between the scapulae,
and plugged by stainless steel pins. Incisions were closed
by surgical staples and swabbed with povidone-iodine
solution. Each rat received a s.c. injection of buprenor-
phine hydrochloride (Buprenex; 0.3 ?g rat-1) to control
pain and an i.p. injection of 50,000 U kg-1 of penicillin G
benzathine and penicillin G procaine in an aqueous sus-
pension (Durapen) and was housed in a separate cage.
The experiment was started 48 h later, which involved the
connection of the arterial catheter to a Gould-Statham
pressure transducer (Oxnard, CA). The blood pressure was
displayed on a Grass polygraph (model 7D, Grass Instru-
ments Co., Quincy, MA). Heart rate was computed from
blood pressure wave-forms by a Grass tachograph and was
displayed on another channel of the polygraph. Blood
samples were collected prior to each experiment for the
analysis of serum testosterone and 17?-estradiol levels.
Experiments were performed in strict accordance with
institutional animal care and use guidelines, and in
accordance with the principles and guidelines of the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals.
Orchiectomy
Bilateral orchiectomy was performed as described in pre-
vious studies [18] and according to the protocol of the
Department of Comparative Medicine, East Carolina Uni-
versity. Under methohexital sodium (50 mg kg-1, i.p.)
anesthesia, a small surgical incision was made in the
center of the scrotum. Each testicle was exposed through
the surgical orifice. The ductus deferens and main arteries
and veins were isolated, ligated, and severed allowing the
Effect of androgen receptor blockade on testosterone and 17?-estradiol levelFigure 6
Effect of androgen receptor blockade on testoster-
one and 17?-estradiol level. Testosterone levels (A) and 
17?-Estradiol levels (B) subsequent to flutamide (5, 15, or 30 
mg/kg) treatment in conscious unrestrained male rats. Data 
are means ± SEM. Numbers in parentheses are number of 
observations. One-Way Analysis of Variance (ANOVA) fol-
lowed by Fisher's Least Significant Difference post hoc analy-
sis, * P < 0.05 vs. vehicle.
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testicle and epididymis to be removed. The incision was
then closed, sutured and swabbed with povidone-iodine
solution. The sham operation involved the exposure of
the testes without isolation. The post-operative procedure
was implemented as previously described. Finally, the rats
were housed in separate cages and allowed free access to
food and water.
Radioimmunoassays
The commercially available radioimmunoassay "Coat-A-
Count Total Testosterone" and "Double Antibody Estra-
diol" kits were used for the analysis of serum testosterone
and 17?-estradiol, respectively, and were purchased from
Diagnostic Products Corporation (Los Angeles, CA).
Protocols and experimental groups
Effect of androgen depletion on baroreceptor reflex control of heart 
rate
Two groups of rats (orchiectomized 3 weeks earlier at
250–275 g; orchiectomized: n = 21 and sham: n = 14)
weighing 325–350 g at the time of the experiment, were
used to investigate whether androgen depletion attenu-
ates the baroreflex heart rate response in conscious unre-
strained rats. The rats were allowed to acclimatize to
laboratory conditions for at least 2 h prior to experimen-
tation. After connecting the rat to the pressure transducer,
blood samples (0.6 ml) were collected, from the femoral
artery, for measurements of serum testosterone level. A
period of 30 min was then allowed for further stabiliza-
tion of blood pressure and heart rate. Baroreflex curves
were constructed in all rats by the i.v. bolus injection of
randomized doses of phenylephrine (1–16 ?g kg-1) (a
pressor agent) at 5-min intervals. Phenylephrine was dis-
solved in saline and administered in varying volumes of a
stock concentration (36 ?g ml-1) of phenylephrine to
achieve the desired doses. Each experiment lasted approx-
imately 1 h. The peak changes in mean arterial pressure
and heart rate, obtained following phenylephrine injec-
tions, were used for the construction of the baroreflex
curves.
Effect of androgen receptor blockade on baroreceptor reflex control 
of heart rate
The rats in each of 3 groups (5 mg kg-1: n = 9, 15 mg kg-1:
n = 12, and 30 mg kg-1: n = 18, Table 1) weighing 325–350
g, received one of 3 doses of the competitive antiandrogen
flutamide (5, 15, or 30 mg kg-1, s.c.), 20–24 h prior to the
experiment. The control group (n = 9, Table 1) received an
equal volume of the vehicle (sesame oil). Baroreflex
bradycardia was assessed as previously described.
Drugs
Phenylephrine hydrochloride (Sigma Chemical Co., St.
Louis, MO), flutamide (Sigma Chemical Co., St. Louis,
MO), sesame oil (Sigma Chemical Co., St. Louis, MO),
methohexital sodium (Eli Lilly and Company, Indianapo-
lis, IN), buprenex (buprenorphine hydrochloride; Rickitt
& Colman, Richmond, VA), povidone-iodine solution
(Norton Co., Rockford, IL), and Durapen (penicillin G
benzathine and penicillin G procaine; Vedco, Overland
Park, KS) were purchased from commercial vendors.
Statistical analysis
Values are expressed as means ± SEM. The relationship
between increases in mean arterial pressure (Mean Arte-
rial Pressure = diastolic pressure + one-third {systolic –
diastolic pressures}) and associated decreases in heart
rate was assessed by regression analysis for individual ani-
mals as described in our previous studies [17]. The regres-
sion coefficient (slope of the regression line) expressed as
beats min-1 mmHg-1 was taken as an index of baroreflex
bradycardia [17]. Analysis of variance (ANOVA) followed
by Fisher's Least Significant Difference post hoc analysis
was used for multiple comparisons. The Student's t-test
was used in the analysis of unpaired data, with the level of
significance set at P < 0.05. In accordance with reported
criteria, control rats possessing (i) baroreflex bradycardia
values with significant (P < 0.05) correlation coefficients
greater than or equal to 0.8 [19], and (ii) serum testoster-
one levels greater than or equal to 60 ng/dl [20] were
included in the data analysis.
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